PMID: 9174203Jun 1, 1997Paper

Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect

Antimicrobial Agents and Chemotherapy
F J BoswellR Wise

Abstract

Time-kill kinetics of BAY 12-8039 were studied at two inocula against three strains each of Bacteroides fragilis, Escherichia coli, Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pyogenes. The postantibiotic effects of BAY 12-8039 were studied on three strains each of E. coli, S. aureus, H. influenzae, Streptococcus pyogenes, and Streptococcus pneumoniae. The pharmacodynamic data demonstrated that BAY 12-8039 has marked activity against gram-positive and gram-negative organisms (under both anaerobic and aerobic conditions) and anaerobes. BAY 12-8039 also exhibited a postantibiotic effect of >1 h for all strains except one E. coli strain.

References

Nov 1, 1992·The Journal of Antimicrobial Chemotherapy·C S LewinJ T Smith
Sep 1, 1991·The Journal of Antimicrobial Chemotherapy·M A CooperR Wise
Jan 1, 1989·The Journal of Antimicrobial Chemotherapy·D J GriggsR Wise
Feb 1, 1995·Antimicrobial Agents and Chemotherapy·R A ZabinskiJ C Rotschafer

❮ Previous
Next ❯

Citations

Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A DalhoffG Tillotson
Mar 5, 2004·The Annals of Otology, Rhinology, and Laryngology·Paulo Borges DinisJosé Guimarães Morais
Oct 1, 2004·Drugs·Gillian M Keating, Lesley J Scott
Jul 5, 2005·Expert Opinion on Investigational Drugs·A Dalhoff
Dec 13, 2006·Treatments in Respiratory Medicine·George G ZhanelDaryl J Hoban
Oct 16, 2004·Expert Review of Anti-infective Therapy·Juan-Pablo Caeiro, Paul B Iannini
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·V Rodriguez-CerratoG H McCracken
Feb 13, 2020·Journal of Cataract and Refractive Surgery·Neal H Shorstein, Susanne Gardner
May 17, 2001·Antimicrobial Agents and Chemotherapy·K HamamotoS Arai
Mar 25, 2008·Therapeutics and Clinical Risk Management·David Rp Guay
Jul 5, 2005·Expert Opinion on Investigational Drugs·A P MacGowan
Dec 31, 1998·Antimicrobial Agents and Chemotherapy·E MiyazakiW R Bishai
Feb 22, 2002·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Alasdair P. MacGowanH. Alan Holt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.